Our previous studies had validated GCS inhibition as a therapeutic strategy for synucleinopathies in GbaD409V/D409V mice by demonstrating a significant improvement in CNS pathology and the associated memory deficit following treatment27. Here, UGCG is linked to synucleinopathy.